SOMATULINE L.P. 30 mg, powder and solvent for injectable suspension (IM) with extended release bottle, 2 ml
Active ingredients: Lanreotide acetate, Lanreotide
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended releasebottle, 2 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SOMATULINE L.P. 30 mg, poudre et solvant pour suspension injectable (IM) à libération prolongée
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre - 1 ampoule(s) en verre de 2 ml avec 1 seringue(s) et 2 aiguille(s)
- Marketing authorisation holder
- IPSEN PHARMA
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 16 Aug 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67919092CIP73373523CIP133400933735234Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LANRÉOTIDE BASEpoudre | 0,030 g · un flacon | FT |
| ACÉTATE DE LANRÉOTIDEpoudre | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.